Chief Commercial Officer · BioNTech SE · BioNTech SE — Option (right to buy)
Side
A
Value
—
Shares
12.6K
Price
—
Executed
May 12, 2026
Disclosed
May 13, 2026
Disclosure timeline1 days from execution to publication · legal deadline 2 business days
May 12 executedMay 13, 2026 disclosed
BNTX · daily
Yahoo Finance chart API
◉This trade, on the day it was made▼Disclosure●Material company filing◯Other disclosed buy◯Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Grant or award — administrative, little informational value
Relative size+1 / 25
No reported dollar value · new position
Filing timing0 / 15
Disclosed 1 business day after execution (deadline: 2)
Historical behavior+8 / 15
First recorded trade by this actor in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Hanekamp Annemarie filed this Form 4 reporting a grant or award of BNTX on May 12, 2026. It became public on May 13, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
Chief Commercial Officer
Hanekamp Annemariecik:0002118987
Issuer
BioNTech SEcik:0001776985
Revision history · 0
No field has changed since this record was first ingested.
